Shield Therapeutics

PDMR Transaction Notification

RNS Number : 3927R
Shield Therapeutics PLC
05 March 2021
 

 

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

 

PDMR Transaction Notification

 

London, UK, 05 March 2021:   Shield Therapeutics plc (LSE:STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru®, announces that Hans Peter Hasler, Non-Executive Chairman, acquired 200,000 Ordinary Shares in the Company on 05 March 2021 at an average price of 0.375 pence per share. Following the transaction, Mr Hasler has a beneficial interest in 500,000 shares.

 

The notification below, which has been made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them:

 

1. 

Details of the person discharging managerial responsibilities / person closely associated

a. 

Name

Hans Peter Hasler

2. 

Reason for the notification

a. 

Position/status

Non-Executive Chairman

b. 

Initial notification

/Amendment

Initial

3. 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a. 

Name

Shield Therapeutics plc

b. 

LEI

213800G74QWY15FC3W71

4. 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a. 

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5p each in the capital of the Company

 

 

 

ISIN of Ordinary Shares: GB00BYV81293

b. 

Nature of the transaction

 

Acquisition of Ordinary Shares

 

c. 

Price(s) and volume(s)

 

Price(s)

 

Volume(s)

£0.375

200,000

d. 

Aggregated information

· Aggregated volume

· Price

 

 

200,000

 

£75,000

 

e. 

Date of the transaction

2021-03-05

f. 

Place of the transaction

London Stock Exchange, AIM Market

 

 

 

 

 

 

 

For further information, please contact:

 

Shield Therapeutics plc

+44 (0) 191 511 8500

Tim Watts (CEO)




Peel Hunt LLP - Nominated Adviser, Joint Broker and Bookrunner

  +44 (0) 20 7148 8900

James Steel / Dr Christopher Golden




finnCap Ltd - Joint Broker and Bookrunner

  +44 (0) 20 7220 0500

Geoff Nash / Matthew Radley / Alice Lane




Walbrook PR - Financial PR & IR Adviser

+44 (0) 20 7933 8780

Paul McManus / Lianne Cawthorne

or [email protected]

 

 

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol)®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUPUUAWUPGGQA